R&D News | pharmaphorum

News

Faron’s Clever-1 drug shows promise in blood cancers

Faron Pharmaceuticals has reported data from a phase 1/2 trial pointing to the potential of its macrophage-directed antibody bexmarilimab as a treatment for blood cancers

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

Sanofi partners BioMap on AI hunt for biologic therapies

Sanofi has added another dimension to the use of artificial intelligence (AI) to seek out new drugs, partnering with BioMap on a project to find biologic therapies in a de

News

Another NASH setback as Akero’s efruxifermin stumbles

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimis

News

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the

News

Bayer backs cell therapy ambition with $250m US facility

Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke

Faron’s Clever-1 drug shows promise in blood cancers

Novo Nordisk’s semaglutide aces another outcomes trial

Sanofi partners BioMap on AI hunt for biologic therapies

Another NASH setback as Akero’s efruxifermin stumbles

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

Bayer backs cell therapy ambition with $250m US facility

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks